meta_pixel
Tapesearch Logo
In Good Company with Nicolai Tangen

HIGHLIGHTS: Thomas Schinecker - CEO of Roche

In Good Company with Nicolai Tangen

Norges Bank Investment Management

In Good Company, Business, Norges Bank, Nicolai Tangen

4.8 • 186 Ratings

🗓️ 22 November 2024

⏱️ 10 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges

What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest health care companies. They discuss Roche’s leadership in cancer treatment, breakthroughs in diagnostics, and the impact of cutting-edge R&D in areas like precision medicine and AI. Schinecker also shares his views on the rapid growth of China’s pharma industry and the challenges Europe faces in keeping up with global clinical trials.


The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Sara Arnesen.




Hosted on Acast. See acast.com/privacy for more information.

Transcript

Click on a timestamp to play from that location

0:00.0

Hi, everybody. Tune in to this short version of the podcast, which we do every Friday for the long version.

0:05.4

Tune in on Wednesdays.

0:07.7

Hi, everyone. I'm Nicola Tangen, the CEO of the Norwegian Soban Wealth Fund.

0:11.6

And today we have Thomas Schenacher, the CEO of Rosh, which is one of the leading healthcare companies in the world.

0:18.7

Roche was founded in 1896, so it's really old. Lots of tradition,

0:24.1

have really innovated in healthcare, saved millions and millions of people. And we are proud

0:29.7

that we own 2.3% of the company worth more than $6 billion. So a big thanks, Thomas,

0:36.1

for joining us today. Thank you very much for the invitation.

0:39.3

So, Thomas, when you drive into Basel, right, you have Roche on one side of the river, Novartis,

0:47.8

on the other side of the river, two of the leading pharma companies in the world. So how come

0:52.1

that this little Swiss town has grown to become one of the

0:55.6

supercenters for biofarmar? I think it's all in the history of that region, starting with the chemical

1:02.0

industry and then later moving into the pharma part of the industry. So I think it's all basically

1:08.3

in the history of that region. And located in the center of Europe, it's all basically in the history of their region.

1:15.3

And located in the center of Europe, it's actually quite ideally located.

1:25.1

In addition, it also has an ecosystem in terms of good universities, good educational system in general. And I think this really attracts a lot of people around the world,

1:28.5

really talented people that can drive the innovation.

1:32.7

You are the leader in cancer. And I read this book called The Emperor of All Melodies

1:39.7

about the incredible progress that's happened in cancer survival rates of the last 50 years.

1:45.9

Could you just briefly take us through the main milestones in that development?

1:49.5

So on the oncology side, I think one of the major breakthroughs was clearly the understanding of our genome.

1:57.6

If you look back in 2003, it costs billions to sequence one genome. If you look back in 2003, it costs billions to sequence one genome and took, I think,

...

Transcript will be available on the free plan in -128 days. Upgrade to see the full transcript now.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Norges Bank Investment Management, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Norges Bank Investment Management and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.